Samary Alaniz Monreal

Samary Alaniz Monreal

Faculty of health sciences, Universidad Anáhuac, Huixquilucan, México, Mexico
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2023 in Molecules
Verified
Journal Article
Open access
PDF file
DSDenise Franco-San Sebastián
Denise Franco-San Sebastián
Samary Alaniz MonrealSamary Alaniz Monreal
Samary Alaniz Monreal
GRGriselda Rabadán-Chávez
Griselda Rabadán-Chávez
NVNatalia Vázquez
Natalia Vázquez
MHMarcela Hernández
Marcela Hernández
GGGabriela Gutiérrez-Salmeán
Gabriela Gutiérrez-Salmeán
Overweight and obesity are present in about three-quarters of the adult population in Mexico. The inflammatory mechanisms subjacent to visceral white adipose tissue are accountable for the initiation and development of cardiometabolic alterations, including type 2 diabetes. Lifestyle changes are pillars within its therapeutics and, thus, current dietary modifications should include not only hypocaloric prescriptions with balanced macronutrient intake, preferably by increasing the amount of whole grains, fruits, vegetables, nuts and legumes, but in concomitance, bioactive substances, such as anthocyanins, have been correlated with lower incidence of this disease.

7 January 2025 in Medicina
Verified
Journal Article
Open access
PDF file
MAMelchor Alpizar
Melchor Alpizar
SSamantha Estefania Olguín Reyes
Samantha Estefania Olguín Reyes
AEAndrea Medina Estévez
Andrea Medina Estévez
JLJulieta Alejandra Saturno Lobos
Julieta Alejandra Saturno Lobos
JCJesús Manuel De Aldecoa Castillo
Jesús Manuel De Aldecoa Castillo
DSDulce María Fernanda Alpízar Sánchez
Dulce María Fernanda Alpízar Sánchez
Introduction: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) stems from disrupted lipid metabolism in the liver, often linked to obesity, type 2 diabetes, and dyslipidemia. In Mexico, where obesity affects 36.9% of adults, MASLD prevalence has risen, especially with metabolic syndrome affecting 56.31% by 2018. MASLD can progress to Metabolic Dysfunction-Associated Steatohepatitis (MASH), affecting 5.27% globally, leading to severe complications like cirrhosis and hepatocellular carcinoma. Background: Visceral fat distribution varies by gender, impacting MASLD development due to hormonal influences. Insulin resistance plays a central role in MASLD pathogenesis, exacerbated by high-fat diets and specific fatty acids, leading to hepatic steatosis. Lipotoxicity from saturated fatty acids further damages hepatocytes, triggering inflammation and fibrosis progression in MASH. Diagnosing MASLD traditionally involves invasive liver biopsy, but non-invasive methods like ultrasound and transient elastography are preferred due to their safety and availability. These methods detect liver steatosis and fibrosis with reasonable accuracy, offering alternatives to biopsy despite varying sensitivity and specificity. Conclusions: MASLD as a metabolic disorder underscores its impact on public health, necessitating improved awareness and early management strategies to mitigate its progression to severe liver diseases.